SEC Company Response from Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — Nov 19, 2013
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: Nov. 19, 2013 · CIK: 0001262104 · Accession: 0001193125-13-446840
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-179590
Referenced dates: November 18, 2013
Letter
[Letterhead of MEI Pharma, Inc.]
November 19, 2013
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey P. Riedler, Assistant Director
Daniel Greenspan
Austin Stephenson
Re: MEI Pharma, Inc.
Post-Effective Amendment No. 2 to Form S-1 on Form S-3
Filed November 12, 2013
File No. 333-179590
Ladies and Gentlemen:
This letter is being filed in response to a comment from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) transmitted by letter dated November 18, 2013, to Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma, Inc. (the “Company”), with respect to the above-referenced registration statement on Form S-3.
This letter recites the Staff’s comment and then provides the Company’s response to that comment.
1. Please amend your registration statement to incorporate by reference the Form 10-Q filed on November 8, 2013.
Response:
Concurrently with this letter, the Company is filing an amendment to its registration statement that incorporates by reference the Form 10-Q filed on November 8, 2013.
* * * * *
If you have any questions concerning the above response, please contact the undersigned at (858) 792-0865 or Thomas M. Zech at (858) 369-7111.
Sincerely,
MEI PHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
[Letterhead of MEI Pharma, Inc.]
November 19, 2013
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
100 F Street,
N.E.
Washington, D.C. 20549
Attention:
Jeffrey P. Riedler, Assistant Director
Daniel Greenspan
Austin Stephenson
Re:
MEI Pharma, Inc.
Post-Effective Amendment No. 2 to Form S-1 on Form S-3
Filed November 12, 2013
File No. 333-179590
Ladies and Gentlemen:
This letter is being filed in response to a comment from the staff (the “Staff”) of the Securities and Exchange Commission
(the “Commission”) transmitted by letter dated November 18, 2013, to Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma, Inc. (the “Company”), with respect to the above-referenced
registration statement on Form S-3.
This letter recites the Staff’s comment and then provides the Company’s response to that
comment.
1.
Please amend your registration statement to incorporate by reference the Form 10-Q filed on November 8, 2013.
Response:
Concurrently with this letter,
the Company is filing an amendment to its registration statement that incorporates by reference the Form 10-Q filed on November 8, 2013.
* * * * *
If you have any
questions concerning the above response, please contact the undersigned at (858) 792-0865 or Thomas M. Zech at (858) 369-7111.
Sincerely,
MEI PHARMA, INC.
By:
/s/ Daniel P. Gold
Daniel P. Gold
President and Chief Executive Officer
Securities and Exchange Commission
November 19, 2013
Page 2
cc:
Steven A. Navarro
Finnbarr D. Murphy
Morgan, Lewis & Bockius LLP
101 Park Avenue
New York, NY
10178